Table 6. Differences between studies... | American Society of Hematology

Table 6.

Differences between studies

Characteristic	CIBMTR	Current study
Centers	Multiple	Single
Donor types	Unrelated	Related and unrelated
HLA-A, -B, -C, -DRBI, and -DQB1 mismatching included	No	Yes
No. of recipients, candidate SNP study	Up to 2887	Up to 2560 for discovery
No. of recipients, genome-wide study	1970 for discovery	Up to 2560 for discovery
Recipient diseases	AML, ALL, MDS	Any hematologic malignancy
End points	OS, PFS, NRM, RM	NRM, RM
End point adjudication	Yes	No
No. of individual candidate variants	47	122
Candidate SNP genetic models	Allelic	Allelic, dominant, recessive
Adjustment for clinical covariates	Yes	No
Truncation of follow-up	1 y	None
Tested recipient SNP allele mismatching	Yes	No
GWAS scope	Exomes	Whole genome
Statistical replication or validation	Metaanalysis	3:2 discovery/replication split
Gene-level analysis	Yes	No

Characteristic	CIBMTR	Current study
Centers	Multiple	Single
Donor types	Unrelated	Related and unrelated
HLA-A, -B, -C, -DRBI, and -DQB1 mismatching included	No	Yes
No. of recipients, candidate SNP study	Up to 2887	Up to 2560 for discovery
No. of recipients, genome-wide study	1970 for discovery	Up to 2560 for discovery
Recipient diseases	AML, ALL, MDS	Any hematologic malignancy
End points	OS, PFS, NRM, RM	NRM, RM
End point adjudication	Yes	No
No. of individual candidate variants	47	122
Candidate SNP genetic models	Allelic	Allelic, dominant, recessive
Adjustment for clinical covariates	Yes	No
Truncation of follow-up	1 y	None
Tested recipient SNP allele mismatching	Yes	No
GWAS scope	Exomes	Whole genome
Statistical replication or validation	Metaanalysis	3:2 discovery/replication split
Gene-level analysis	Yes	No

ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.